secwatch.observer — SEC 8-K summary
======================================

Issuer:     Organon & Co. (OGN)
CIK:        0001821825
Form:       8-K
Filed at:   2023-02-16T23:59:59+00:00
Accession:  0001104659-23-022617
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Organon reports FY 2022 revenue $6.2B (-2% as-reported); Q4 GAAP EPS $0.42, provides 2023 guidance
--------------------------------------------------------------------------------

- FY 2022 revenue $6.174B, down 2% as-reported, up 4% ex-FX; diluted GAAP EPS $3.59, non-GAAP adjusted $5.03.
- Q4 2022 revenue $1.485B, down 7% as-reported, up 1% ex-FX; GAAP EPS $0.42, non-GAAP adjusted $0.81.
- All three franchises grew on constant-currency basis in FY 2022; Nexplanon up 11% ex-FX, Biosimilars up 17% ex-FX.
- Q4 included $36M inventory charges and $8M sales return reserve due to Heist facility market action.
- 2023 guidance: revenue $6.15B-$6.45B; Adjusted EBITDA margin 31%-33%; quarterly dividend $0.28/share declared.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1821825/000110465923022617/0001104659-23-022617-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1821825/000110465923022617/tm234187d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-022617

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer